|
Press Releases |
|
|
|
Wednesday, March 23, 2022 |
|
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities |
Singapore Exchange-listed Alset International Ltd (SGX Stock Code: 40V) ("Alset", the "Company" or together with its subsidiaries, the "Group) wishes to announce that the Company has plans to embark on cryptocurrency mining business through its subsidiary Alset Mining Pte. Ltd. ("Alset Mining"). more info >> |
|
Monday, February 21, 2022 |
|
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option |
Alset Capital Acquisition Corp. (the "Company") announced on February 3, 2022 the closing of its initial public offering of 7,500,000 units at $10.00 per unit (the "Offering"). more info >> |
|
Monday, October 5, 2020 |
|
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc. |
Document Security Systems, Inc. today announced its wholly owned subsidiary Impact BioMedical, Inc. ("Impact BioMedical") has formed a new wholly owned subsidiary, Innate Immune, Inc. ("Innate Immune"), to initiate efficacy testing of a pancoronavirus vaccine, a special type of vaccine designed to protect against multiple coronaviruses. more info >> |
|
Friday, September 18, 2020 |
|
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance |
Document Security Systems, Inc. (NYSE American: DSS) today announced its wholly owned subsidiary Impact BioMedical, Inc., through its subsidiary Global BioLife, Inc., completed efficacy testing of its proprietary 3F Antiviral Biofragrance at a biosafety level 3 containment facility at an independent university. more info >> |
|
Friday, July 31, 2020 |
|
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development |
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly-owned subsidiary Impact Biomedical Inc. ("Impact"), announced today the initiation of Quantum, their research program designed to solve the impending pharmaceutical patent cliff threat. more info >> |
|
Wednesday, June 24, 2020 |
|
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance |
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that they proved in vitro success of Equivir and 3F Biofragrance against COVID-19 in independent laboratory testing. more info >> |
|
Wednesday, June 17, 2020 |
|
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal |
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that their COVID-19 research with Global Research and Discovery Group Sciences ("GRDG"), conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. ("Vilotos"), was published in the peer-reviewed scientific journal Molecules on June 11, 2020. more info >> |
|
Monday, June 1, 2020 |
|
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts |
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary, Impact Biomedical Inc., would like to update its stakeholders on its suite of antiviral and medical technologies. more info >> |
|
Friday, April 24, 2020 |
|
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts |
SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced recently that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). more info >> |
|
Wednesday, March 18, 2020 |
|
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak |
Singapore Exchange-listed Singapore eDevelopment Limited has announced that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. ("GRDG"), recently conducted molecular docking studies, utilizing advanced computational models, which indicate Linebacker and Equivir successfully inhibit infection of SARS-CoV-2, the virus responsible for the COVID-19 outbreak. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
王朝酒业公布2023年全年业绩
Mar 28, 2024 17:45 HKT/SGT
|
|
|
王朝酒業公佈2023年全年業績
Mar 28, 2024 17:42 HKT/SGT
|
|
|
Dynasty Fine Wines Announces 2023 Annual Results
Mar 28, 2024 17:35 HKT/SGT
|
|
|
东软教育:内生高质量发展 数字化赋能打开长远增长空间
Mar 28, 2024 16:45 HKT/SGT
|
|
|
東軟教育:內生高質量發展 數字化賦能打開長遠增長空間
Mar 28, 2024 16:42 HKT/SGT
|
|
|
Fosun's Next Step: "Deep Mining" for Stable Profits
Mar 28, 2024 16:26: JST
|
|
|
Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System
Mar 28, 2024 16:45 JST
|
|
|
浙江沪杭甬:业绩稳健向好 积极回馈股东 分红总额增长17.7%
Mar 28, 2024 15:43 HKT/SGT
|
|
|
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
Mar 28, 2024 15:42: JST
|
|
|
浙江滬杭甬:業績穩健向好 積極回饋股東 分紅總額增長17.7%
Mar 28, 2024 15:37 HKT/SGT
|
|
|
2023年收入、利潤實現「雙增長」 復星下一步:「深挖礦」,穩盈利
Mar 28, 2024 15:31 HKT/SGT
|
|
|
Fosun's Next Step: "Deep Mining" for Stable Profits
Mar 28, 2024 15:26 HKT/SGT
|
|
|
Turning Loss into Profit in 2023: IGG Achieved over HK$430 million in 2H23
Mar 28, 2024 15:25: JST
|
|
|
国际债券持有人特别团体(“持有人特别团体”)指示受托人 向香港上市公司希教国际控股(1765.HK)送达清盘呈请书
Mar 28, 2024 15:21 HKT/SGT
|
|
|
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
Mar 28, 2024 14:42 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|